Skip to main content
Clinical Trials/NL-OMON31663
NL-OMON31663
Not yet recruiting
Phase 3

Platelet Transfusion in Cerebral Haemorrhage - PATCH

Academisch Medisch Centrum0 sites190 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 3
Status
Not yet recruiting
Enrollment
190

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • \- Age 18\-75 years
  • \- Patients with non\-traumatic, supratentorial ICH confirmed by CT
  • \- Haematoma volume \< 150 cc
  • \- Glagow Coma Scale score 8\-15
  • \- Platelet aggregation inhibitors used at least seven days preceding haemorrhage
  • \- Treatment can be initiated within 6 hours after onset of first signs and within 1\* hours of the CT scan
  • \- Pre\-stroke Rankin scale score 0 or 1 (No symptoms, No significant disability despite
  • symptoms; able to carry out all usual duties and activities)

Exclusion Criteria

  • \- Haematoma on CT compatible with epidural, subdural, aneurysmal or arterio\-venous malformation (AVM) haematoma
  • \- Planned surgical evacuation of haematoma within 24 hours after admission
  • \- Presence of intraventricular blood if more than sedimentation in the posterior horns of the lateral ventricles
  • \- Previous adverse reaction after platelet transfusion
  • \- Previously legally incompetent adults
  • \- Death appears imminent
  • \- Known use of vitamin K antagonists (unless INR \< 1\.3\)
  • \- Known thrombocytopenia \< 100 x 10E9/l
  • \- History of coagulopathy

Investigators

Similar Trials